Lifecore Biomedical, Inc. De (LFCR) Preferred Stock Liabilities (2023 - 2025)

Lifecore Biomedical's Preferred Stock Liabilities history runs 3 years deep, the most recent figure standing at $46.1 million for Q2 2025.

• In Q2 2025, Preferred Stock Liabilities rose 8.24% year-over-year to $46.1 million; the TTM figure through May 2025 stood at $46.1 million (up 8.24% YoY), while the FY2025 annual figure was $46.1 million, up 8.24% from the prior year.
• Preferred Stock Liabilities was $46.1 million for Q2 2025 at Lifecore Biomedical, up from $45.2 million in the prior quarter.
• In the past five years, Preferred Stock Liabilities ranged from a high of $46.1 million in Q2 2025 to a low of $38.5 million in Q1 2023.
• Historically, Preferred Stock Liabilities has averaged $42.2 million across 3 years, with a median of $42.2 million in 2024.
• The sharpest annual moves came in 2024 and 2025: Preferred Stock Liabilities gained 8.34% in 2024, then climbed 8.24% in 2025.
• A 3-year view of Preferred Stock Liabilities shows it stood at $40.9 million in 2023, then advanced by 8.28% to $44.3 million in 2024, then climbed by 4.03% to $46.1 million in 2025.
• The last three Preferred Stock Liabilities figures came in at $46.1 million (Q2 2025), $45.2 million (Q1 2025), and $44.3 million (Q4 2024), per Business Quant data.